President Trump on Thursday announced a deal that could significantly expand access for millions of Americans to hugely popular obesity drugs by reducing the price to as little as $150 a month.
The Trump administration’s agreements with the drugmakers Novo Nordisk and Eli Lilly would save consumers and the government considerable money on Wegovy, Zepbound and two obesity pills that are exp
Continue Reading on New York Times
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.